Protalix BioTherapeutics, Inc. PLX R2K

Q: What is the current share price of Protalix BioTherapeutics, Inc. (PLX)?

As of 2026-07-14 21:23 PDT, Protalix BioTherapeutics, Inc. (PLX) trades at $2.31 on NYSE American. Its 52-week range is $1.38 to $3.15.

Q: What is the market capitalisation of PLX?

Protalix BioTherapeutics, Inc. (PLX) has a market capitalisation of $186.12M on NYSE American.

Q: What is the P/E ratio of PLX?

PLX trades at a trailing price-to-earnings (P/E) ratio of 12.16. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.51.

Q: What is the return on equity (ROE) of PLX?

PLX has a return on equity (ROE) of 27.27%. Its return on capital employed (ROCE) is -9.85%.

Q: Is PLX a good stock to buy?

This page provides a data-driven analysis of Protalix BioTherapeutics, Inc. (PLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.protalix.com

Company Profile ↓

$2.31

+62.68% 1Y

Mkt Cap$186.12M

P/E12.16

P/B2.51

52W High$3.15

52W Low$1.38

Book Value$0.83

EPS (TTM)$0.19

Company Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 27.3%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 35.9% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 12.2, below the sector median of 25.4.

Healthy Margins

Maintains a net profit margin of 20.1%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.13.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $52.74M (-1.2% YoY); net profit $-6.60M.
Trailing 12 Months Year-on-year growth — revenue +233.7%, earnings -325.2%.
5-Year Trend Long-term compounding — revenue CAGR 35.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	35.94%
1 Year:	233.70%

Compounded Profit Growth

5 Years:	-
1 Year:	-325.24%

Stock Price Performance

1 Year:	+62.68%
6 Months:	+11.59%
3 Months:	+0.87%
1 Month:	+12.68%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 53% of range

$1.38 $3.15

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)55.54 · Neutral

Price Performance

1M+12.68%

3M+0.87%

6M+11.59%

1Y+62.68%

Valuation vs Sector

P/E of 12.16 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 27.3%.
Excellent profit margin of 20.1%.
Compounding revenue at 35.9% over 5 years.
Generates positive free cash flow.

CONS

Trading 26.7% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

12.16

Industry PE

25.41

Forward P/E

3.73

PEG Ratio

Book Value

$0.83

Price to Book

2.51

P/S

2.20

EV/EBITDA

5.90

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

35.94%

Profit 5Y

Revenue (YoY)

233.70%

Earnings (YoY)

-325.24%

Profitability & Returns

ROCE

-9.85%

ROE

27.27%

ROA

14.04%

Profit Margin

20.07%

Op Margin

62.65%

Gross Margin

45.24%

EPS (Latest Qtr)

$0.22

EPS (TTM)

$0.19

Balance Sheet & Liquidity

Debt/Equity

0.13

Quick Ratio

1.97

Current Ratio

3.15

Debt

$8.48M

Total Assets

$102.34M

Current Assets

Working Capital

Ownership

Promoter Holding

3.88%

Chg in Prom Hold

FII / Inst Holding

21.39%

Chg in FII Hold

0.08%

Financial Snapshot

Enterprise Value

$186.12M

Total Revenue (TTM)

$76.38M

EBITDA

$21.31M

Free Cash Flow

$6.78M

Operating Cash Flow

$15.09M

Shares Outstanding

80.57M

Gross Margin

45.24%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PLX Protalix BioTherapeutics, Inc. R2K	2.31	12.16	$186.12M	0.00%	-9.85%	27.27%	35.94%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	2.28M	6.70M	2.42M	2.40M	1.69M	1.34M	1.34M	679.00K	1.77M	4.67M	2.89M	6.36M	7.53M	4.55M	2.01M	663.00K	-	10.44M	12.25M	14.25M	-	21.65M	10.97M	10.79M	11.32M	6.43M	12.05M	16.09M	8.75M	14.18M	9.59M	35.08M	10.35M	3.75M	13.47M	17.96M	10.11M	15.66M	17.85M	33.75M
Gross Profit	1.77M	3.31M	1.08M	1.91M	1.41M	1.11M	1.11M	156.00K	94.00K	422.00K	801.00K	835.00K	1.46M	1.63M	-177.00K	-1.25M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-5.64M	-6.47M	-5.45M	-6.21M	-5.38M	-5.58M	-5.00M	-7.86M	-9.93M	-6.65M	-6.37M	-10.80M	-7.76M	-5.15M	-6.74M	-3.74M	-3.67M	-5.53M	-5.84M	-1.54M	2.20M	4.69M	-2.24M	-2.58M	-3.71M	-9.17M	-1.89M	-1.87M	-5.52M	-3.12M	-2.46M	20.42M	-1.89M	-4.86M	-2.43M	3.99M	-4.14M	1.17M	2.13M	21.15M
Net Income	-5.75M	-7.34M	-6.12M	-8.01M	-5.97M	-5.07M	-3.82M	-8.60M	-10.85M	-7.29M	-59.15M	450.00K	-11.44M	-7.24M	-8.46M	-5.32M	-5.43M	-7.26M	-7.74M	-3.56M	291.00K	1.67M	-4.15M	-4.44M	-5.47M	-11.24M	-4.20M	-2.29M	-5.33M	-3.57M	-3.13M	19.34M	-1.85M	-4.59M	-2.20M	3.24M	-3.62M	164.00K	2.35M	18.32M
Diluted EPS	-	-	-	-	-	-	-	-	-0.11	-	-	-0.06	-	-	-0.06	-	-	-	-	-	-	-	-	-0.14	-0.14	-0.25	-0.09	-0.05	-0.11	-0.07	-0.05	0.21	-0.04	-0.06	-0.03	0.03	-0.05	0.00	0.03	0.22
R&D Expense	7.72M	8.15M	7.08M	8.05M	6.10M	6.02M	5.07M	7.33M	10.01M	6.35M	5.97M	9.30M	7.12M	7.29M	7.48M	10.07M	-	11.70M	13.32M	10.00M	-	10.34M	9.19M	7.69M	7.12M	7.69M	7.28M	8.77M	7.58M	7.39M	5.85M	4.47M	3.67M	2.89M	2.96M	3.00M	3.48M	5.99M	4.47M	5.43M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	388.00K	6.64M	8.39M	34.87M	0	3.52M	4.36M	9.20M	21.08M	34.24M	54.69M	62.90M	38.35M	47.64M	65.49M	53.40M	52.74M
Gross Profit	-3.19M	6.86M	1.44M	26.28M	0	2.89M	3.63M	801.00K	4.01M	-	-	-	-	-	-	-	-
Operating Income	-31.97M	-29.97M	-36.53M	-12.17M	-34.06M	-28.56M	-23.67M	-33.16M	-34.52M	-19.31M	-10.72M	2.71M	-20.46M	-13.01M	10.46M	3.92M	-5.50M
Net Income	-31.44M	-29.00M	-36.53M	-11.62M	-27.79M	-29.94M	58.04M	-29.36M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M	-6.60M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-1.23	-0.22	-0.62	-0.31	0.09	0.04	-0.08
R&D Expense	27.39M	37.69M	37.82M	36.66M	29.23M	27.35M	24.89M	30.41M	32.17M	33.33M	44.62M	38.17M	29.73M	29.35M	17.09M	12.97M	19.57M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	64.73M	51.80M	78.73M	113.33M	78.36M	97.25M	82.25M	72.21M	61.13M	45.39M	67.93M	73.67M	55.79M	84.43M	73.42M	82.35M
Total Equity	44.35M	15.88M	-11.32M	-26.08M	-3.36M	-26.95M	-55.60M	10.87M	-9.96M	-29.46M	-52.88M	-70.32M	-27.04M	-6.04M	-10.64M	33.57M	43.21M	48.23M
Cash & Equivalents	42.60M	81.27M	35.90M	27.00M	52.03M	86.40M	54.77M	76.37M	63.28M	51.16M	37.81M	17.79M	18.27M	38.98M	17.11M	23.63M	19.76M	14.68M
Long Term Debt	-	-	-	6.57M	5.42M	2.37M	912.00K	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	76.05M	77.88M	82.08M	140.28M	133.96M	86.38M	92.20M	101.67M	114.01M	115.71M	94.97M	79.70M	66.43M	50.87M	30.21M	34.12M
Current Liabilities	-	-	18.90M	18.69M	25.75M	26.70M	64.35M	11.23M	66.21M	22.75M	25.35M	40.17M	86.47M	33.18M	32.43M	45.53M	25.62M	26.52M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	44.45M	-38.46M	-23.57M	635.00K	-30.65M	-29.28M	-24.28M	-32.10M	-9.99M	-7.74M	-19.36M	-26.11M	-10.29M	-25.00M	-1.32M	8.67M	-11.99M
Investing Cash Flow	-6.17M	-7.99M	-5.87M	-2.29M	-2.10M	-1.00M	39.39M	-967.00K	-1.12M	-591.00K	-883.00K	-19.95M	18.92M	-5.04M	-16.71M	4.22M	-2.37M
Financing Cash Flow	293.00K	501.00K	20.93M	26.56M	-	-	6.63M	19.70M	-1.42M	-4.75M	0	46.47M	12.08M	8.24M	24.67M	-16.79M	9.33M
Capital Expenditure	-6.20M	-7.86M	-5.71M	-2.07M	-1.89M	-785.00K	-464.00K	-849.00K	-971.00K	-686.00K	-627.00K	-655.00K	-1.46M	-628.00K	-1.15M	-1.28M	-1.64M
Free Cash Flow	38.26M	-46.32M	-29.27M	-1.43M	-32.54M	-30.07M	-24.75M	-32.95M	-10.96M	-8.43M	-19.98M	-26.76M	-11.74M	-25.63M	-2.47M	7.39M	-13.63M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-821.4%	103.3%	17.2%	75.4%	-	82.1%	83.3%	8.7%	19.0%	-	-	-	-	-	-	-	-
Operating Margin %	-8,239.4%	-451.2%	-435.6%	-34.9%	-	-810.6%	-542.4%	-360.5%	-163.8%	-56.4%	-19.6%	4.3%	-53.4%	-27.3%	16.0%	7.3%	-10.4%
Net Margin %	-8,103.1%	-436.6%	-435.6%	-33.3%	-	-849.9%	1,329.9%	-319.2%	-395.9%	-77.3%	-33.4%	-10.4%	-71.9%	-31.3%	12.7%	5.5%	-12.5%
ROE %	-197.9%	256.1%	140.1%	346.1%	103.1%	53.9%	533.8%	294.9%	283.3%	50.0%	26.0%	24.1%	457.0%	140.3%	24.8%	6.8%	-13.7%
ROCE %	-	-65.4%	-110.3%	-23.0%	-39.3%	-203.9%	-27.5%	-206.8%	-69.8%	-54.0%	-205.4%	-14.6%	-50.5%	-55.7%	26.9%	8.2%	-9.9%

Shareholding Pattern

Insiders

3.88%

Institutions

21.39%

Public Float

22.25%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.49%	3.62M	$8.37M
2	MAK Capital One LLC	4.40%	3.54M	$8.20M
3	Renaissance Technologies, LLC	1.52%	1.22M	$2.84M
4	State Street Corporation	1.21%	972.82K	$2.25M
5	Northern Trust Corporation	1.10%	885.45K	$2.05M
6	Geode Capital Management, LLC	1.07%	865.30K	$2.00M
7	Stratos Wealth Partners, Ltd.	0.62%	500.00K	$1.16M
8	Vanguard Portfolio Management LLC	0.54%	432.49K	$1.00M
9	Prospera Financial Services Inc.	0.52%	418.57K	$968.99K
10	Opaleye Management Inc.	0.42%	340.00K	$787.10K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PLX

Google News ue, 14 Jul 2026

Medtronic PLC stock underperforms Tuesday when compared to competitors - MarketWatch

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQOVk5cEhaSGNKVFJ3dEktTnZobTlsN2pkUmZ4a1hOLTZYYkZzOU13MGJ1WWx0TTBtY3hFX2dHWWZuczRqLVNIWGNNUDZKN2ZtU3Y3NTNHam5hanhaVUxaMUNOVzBiMlB0elMtNEJncHlqb2dtRVA4LWtuUmtHVmlMZW5vVlhrUF9YREJHa1…

Google News ue, 14 Jul 2026

GSK plc (GSK.L) Stock Price, News, Quote & History - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE1fNW1lMEwybGFCaExOekF5M1N5Qnk3RFFkbzFla0ZPLVRpRXpOM0VJUjA2dWZ2VUFmZ2ZqeXFIMS1yVVgwM0FmdkpGelZrU0E?oc=5" target="_blank">GSK plc (GSK.L) Stock Price, News, Quote & History</a> …

Google News ue, 14 Jul 2026

Eaton Corporation PLC Stock (ETN) Closed Up by 3.24% on Jul 14: What Investors Need To Know - TradingKey

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOY1VIQ29tWWV5V25sam5PVmNhZ2VFaGVIbUdVRy1iZTB1Z3g1T3BwU3M0OEF6ZzZaX1U0N05TTEd5MWRzUFEzZzA3RnpHQzh4WnNzZGVENlFqXzE5VE1HM2VBdGE2MlBpLW9sMDJCU1ptdnRnb0VfZ3dEejNoamRmOFE4NGZ4UEo2VVE?oc…

Google News Mon, 13 Jul 2026

Seagate Technology Holdings plc's Stock Price Dips to $860.66, Marking a 5.46% Decrease: An In-depth Analysis - Smartkarma

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOTU54WmhiTjAwMmRUemg0WkZwbThHTHI4cFF1ak9fLUlZRjFOaVcwSXRTNUNSMzZyWnFMMktVMWsxdWxIdnZiblBsa1JjUHNmOWlQd1YtWXNsdG5WSm11UEgyejJOYktpVWlhVWdLRFd4MjZpSVhwdXBrWnZ2RVFOenpPajNHTnRGT0JDRV…

Google News hu, 25 Jun 2026

Protalix (NYSE: PLX) investors approve directors, pay and expanded stock plan - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbmpYMFhVOTJDRTF5aXoxcDNyRlFrdHdFbUxzdDFfb2RRVXAydnFOOXNpVi1jdkhyanZyZFZjWEtoNm1ReTRnX3hpeDhKRE5NTDJvSGxzS1RIMFRMaUt0N0YweXNoeDZ0MnJmQTZWU2NxWXVwY2gzaVBuRmtlVmpjdFB5dHJpV3ZuNTBZZF…

Google News Fri, 30 Jan 2026

$PLX stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPeDV5NVBXNWtPX3JmeG1zMm1MUk5uMER2RzZHNUxzcTkxeUNXLWx4S2xTbmlpMXItNzAwdjl3Q2s1WTA5WnBRcHRzWnFZTEtfdmIzUVlEQzJIUnNLaklNVDMyc2xwNHhqNkppc0Y2WGVsZl9GTDZVclByVjBtamRLVWZKU3hfT1FodHhjbG…

PLX — Frequently Asked Questions

What is the current share price of Protalix BioTherapeutics, Inc. (PLX)?

As of 2026-07-14 21:23 PDT, Protalix BioTherapeutics, Inc. (PLX) trades at $2.31 on NYSE American. Its 52-week range is $1.38 to $3.15.

What is the market capitalisation of PLX?

Protalix BioTherapeutics, Inc. (PLX) has a market capitalisation of $186.12M on NYSE American.

What is the P/E ratio of PLX?

PLX trades at a trailing price-to-earnings (P/E) ratio of 12.16. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.51.

What is the return on equity (ROE) of PLX?

PLX has a return on equity (ROE) of 27.27%. Its return on capital employed (ROCE) is -9.85%.

Is PLX a good stock to buy?

This page provides a data-driven analysis of Protalix BioTherapeutics, Inc. (PLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Protalix BioTherapeutics, Inc. PLX R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Medtronic PLC stock underperforms Tuesday when compared to competitors - MarketWatch

GSK plc (GSK.L) Stock Price, News, Quote & History - Yahoo Finance

Eaton Corporation PLC Stock (ETN) Closed Up by 3.24% on Jul 14: What Investors Need To Know - TradingKey

Seagate Technology Holdings plc's Stock Price Dips to $860.66, Marking a 5.46% Decrease: An In-depth Analysis - Smartkarma

Protalix (NYSE: PLX) investors approve directors, pay and expanded stock plan - Stock Titan

$PLX stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

PLX — Frequently Asked Questions

What is the current share price of Protalix BioTherapeutics, Inc. (PLX)?

What is the market capitalisation of PLX?

What is the P/E ratio of PLX?

What is the return on equity (ROE) of PLX?

Is PLX a good stock to buy?

Explore More